AFF1 is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 4 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 4 are open and 0 are closed. Of the trials that contain ALK status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 2 (2 open) and 2 are phase 3 (2 open) [3].

BCL2 is an inclusion eligibility criterion in 7 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain BCL2 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [3].

BCL6 is an inclusion eligibility criterion in 7 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain BCL6 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ELL status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 7 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain MYC status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].